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S276 Poster Session IIMethods:We performed a retrospective analysis of our patients
with CLL/Pro-lymphocytic leukemia (PLL) who underwent Al-
SCT at our center between August 1989 and February 2009.
The objective of this study is to evaluate the overall survival
(OS), relapse free survival (RFS), acute and chronic graft versus
host disease (aGVHD, cGVHD). We also compared the inten-
sity of conditioning regimens (conventional: CIC Vs reduced:
RIC), donor type, (matched sibling: MSD vs matched unre-
lated: MUD), graft source (bone marrow: BM vs peripheral
blood: PB) and their impact on OS, RFS, aGVHD and
cGVHD.
Results:There are 59 patients available for review. Patients char-
acteristics are listed in table 1. There were a variety of condition-
ing regimens; for the CIC, 36 pts. received Busulfan based
regimens and 10 pts. Total Body Irradiation based regimens, for
the RIC 13 pts. received different fludarabine based regimens.
Donor types were 48 MSD and 11 MUD. Source was BM in
27 and PB in 32 pts. Most (43/59 pts) received CyA-MTX as
the GvHD prophylaxis but 12 and 4 pts. received Mycophenolate
and Campath with CyA respectively. The median follow up is 45
months (7-237). The median survival time is 115 months with a 5
year survival probability of 57% (95% CI: 0.43-0.68). OS was not
statistically significantly different when comparing type of condi-
tioning or graft source, however a significant improvement in
OS with MSD type over MUD, (P value5 0.0007). The 3-year
RFS is 48% (95% CI: 0.35-0.60) with no statistically significant
difference according to regimen intensity and graft source, with
a significant superior outcome for MSD Vs MUD (P val-
ue5 0.002). Grade 2-4 aGvHD was seen in 40 cases. The cumu-
lative rates of aGvHD 2-4 are not different between the
conditioning, donor type and graft source. Forty-one cases
(68%) experienced cGvHD (18% limited,50% extensive) with no
difference according to regimen intensity and donor type, al-
though a significantly increased incidence in the PB group (P val-
ue5 0.03). Causes of death include infection (40%), GVHD
(33%), relapse (18%) and VOD (9%).
Conclusions: Acceptable survival post Al-SCT is possible in CLL
although TRM is significant. This retrospective analysis demon-
strates inferior survival for MUD recipients and similar outcomes
when comparing RIC and CIC regimens.
Table 1. Patients characteristicsPts studied , n. 59
Diagnosis : CLL / PLL 54 / 5
Mean age (range), y 46 (27-67)
Gender (F /M), n. 19 / 40
Number of prior regimens, mean (range) 4 (1-9)
Prior Purine analogue 84 %
Prior Rituximab 11 %318
OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
CHILDREN WITH SEVERE APLASTIC ANEMIA. TEN YEARS EXPERIENCE
IN A LARGE PEDIATRIC TRANSPLANT CENTRE
Zaidman, I.1, Schecter-Finkelstein, T.2, Doyle, J.2, Gassas, A.2 1Rambam
Health Care Campus, Haifa, Israel; 2Hospital for Sick Children, Toronto,
ON, Canada
Severe aplastic anemia (SAA) in children is a rare and serious dis-
ease. The best potential cure is allogeneic hematopoietic stem cell
transplantation (SCT). Our objective herein was to review the out-
come of all children who received SCT for a diagnosis of SAA be-
tween 1998-2008 in the Hospital for Sick Children, Toronto.
Fifty-eight children were included in the study. Median age at
SCT was 10.1 years (range 1.6-17 yrs). Median time from diagnosis
to SCT was 8.8 months (range 1-142 months). Stem cell source was
related in 38; living unrelated in 18 and 2 patients received cord pro-
genitor stem cells.
Twenty-seven patients received immunosuppressant therapy
prior to SCT. Conditioning regimen for the related donors in-cluded cyclophosphamide and antithymocyte globulin (ATG).
For the unrelated, either a single dose total body irradiation
(TBI) 200 cGy or fludarabine was added. Overall survival for
the whole group was 84%. In a univaraite analysis, factors af-
fecting survival were: stem cell source (related 90%; unrelated
71%); type of SAA (idiopathic 90%; post hepatitis or drug re-
lated 70%; possible hereditary 60%); previous immunossupres-
sive therapy and multiple transfusions (of 10 patients who
died, 8 were treated with 1 or 2 courses of immunossupressive
therapy and 6 of them had more than 20 blood transfusions be-
fore SCT).
Incidence of acute and chronic graft-versus host disease (GVHD)
were 29% and 14% respectively with 6 out of 8 patients with chronic
GVHDwere recipient of unrelated donors. Ten patients died due to
transplant related mortality (TRM) and seven were recipient of un-
related donors. Causes of death were: sepsis, severe VOD, CMV in-
fection and multiorgan failure.
Long term chimerism testing showed 54% of the patients con-
tinued to have full donor status, 22% are stable mixed chimerism
and 4% with decreased chimerism; 15% suffered engraftment fail-
ure (5%-primary and 10%-secondary) and 5% of patients died be-
fore engraftment and were not evaluable for engraftment. Of the 9
patients with primary and secondary graft failure 6 had unrelated
donor.
In conclusion: Our results suggest that factors affecting prognosis
of children with SAA treated with SCT are: etiology of SAA, previ-
ous immunosuppressant therapy, multiple transfusions and type of
donor. Furthermore, engraftment failure continues to be a problem
in particular for recipient of unrelated donors.319
RELATION OF TNFA, TNFB AND TNFRII GENE POLYMORPHISMS TO OUT-
COMES AFTER UNRELATED HAEMATOPOIETIC CELL TRANSPLANTATION
WITHIN CHINESE POPULATION
Xiao, H., Lai, X., Wu, G., Luo, Y., Shi, J., Tan, Y., Han, X., Zhu, X.,
Zhu, J., Xie, W., He, J., Cai, Z., Lin, M., Ye, X., Huang, H. The First
Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
Zhejiang, China
Background: The genes code TNFa (TNFA), TNFb (TNFB) and
TNF receptor II (TNFRII) contain multiple single nucleotide poly-
morphisms (SNPs). The present study was designed to test associa-
tion of these genes polymorphisms with outcomes after unrelated
HSCT within Chinese population.
Methods: A total of 138 pairs of donors and recipients, who
had undergone HSCT from 2001 to 2009 at our center, were
tested for TNFA-1031(T.C), -863(C.A), -857(C.T),
-238(G.A), TNFB + 252(A.G) and TNFRII codon 196
(T.G) genotypes.
Results: (1) Recipients and/or donors with TNFA-857 C/C geno-
type or TNFB + 252 G allele-positive had a higher incidence of
aGVHD (P\0.05). TNFRII 196 T/T genotype in donors side
or recipients side showed a stronger trend toward development of
aGVHD (in donor side: P5 0.028; in recipient side: P5 0.086).
When these effects were analyzed only in 96 pairs of HLA matched
cases, donor and/or recipient TNFA-857 and TNFB + 252 geno-
type also affected aGVHD incidence. The influence of TNFRII
genotype was not significant except the recipient type showed
a trend (P5 0.074).The genotypes of TNFA -1031, -863 and
-238 were not found to be associated with the risk of aGVHD.
(2) TNFA-857, TNFB + 252 and TNFRII 196 polymorphic fea-
tures, together with other factors were subjected to multivariate
analysis for aGVHD. Myeloablative conditioning(RR5 3.771,
P5 0.004), donor with TNFA-857C/C genotype (RR5 2.29,
P5 0.006) and recipient with TNFB + 252 G allele-positive
(RR5 1.789, P5 0.036) were found to significantly contribute to
the development of aGVHD. Donor-recipient gender was found
to be a less significant factor (P5 0.079). As to grade II-IV
aGVHD, myeloablative conditioning (RR5 3.929, P5 0.022),
HLA mismatching (RR5 1.691, P5 0.048) and donor with
TNFA-857 C/C genotype (RR5 3.748, P5 0.002) were found to
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positive was a less significant factor (RR5 1.823, P5 0.063). (3)
Relapse was observed more frequently among patients who had
not previously developed aGVHD (P5 0.03). Except TNFRII
196 T/T genotype in recipients side was related to lower relapse
rate(P5 0.05), no significant association was found between cyto-
kine genes polymorphisms with cGVHD, relapse and overall
survival.
Conclusions: These results, which is the first report of TNFA,
TNFB and TNFRII polymorphic features of Chinese population
with the outcomes of HSCT, suggest an interaction of TNFA-
857, TNFB + 252 genotypes on risk of aGVHD.320
RAPID SWITCH TO DONOR-TYPE DOMINANT CHIMERISM AND EARLY
LYMPHOCYTE RECOVERY FOLLOWING REDUCED-INTENSITY CORD
BLOOD TRANSPLANTATION
Uchida, N.1, Wake, A.1, Yamamoto, H.1, Yoneyama, A.2, Nishida, A.1,
Shimazu, H.1, Nakano, N.1, Ishiwata, K.1, Tsuji, M.1, Asano-
Mori, Y.1, Makino, S.3, Masuoka, K.4, Taniguchi, S.1 1Toranomon Hos-
pital, Tokyo, Japan; 2Toranomon Hospital, Tokyo, Japan; 3Toranomon
Hospital, Tokyo, Japan; 4Mishuku Hospital, Tokyo, Japan
Although immune cells in cord blood (CB) are immature, several
lines of evidence suggested that they are potentially active from
very early timing post-transplant, such as severe immune reaction
observed at around day 9 (Kishi, Transplantation 2005, Barker,
BMT Tandem meetings 2009), or the impact of HLA disparity
in GVH direction on engraftment failure (Matsuno, Blood 2009).
We conducted a retrospective study to investigate the kinetics of
donor-recipient chimerism and lymphocyte recovery (LR) during
early period after CBT. Data were collected from 109 patients
who underwent first CBT using fludarabine (Flu)-containing regi-
men since June 2007 to Feb. 2009 at Toranomon Hospital. Pa-
tients who had non-malignant diseases, died within 30 days, or
had disease progression before engraftment or within 30 days
post-transplant were excluded, and 47 were subjected to the analy-
sis. 21 out of 26 recipients of unrelated bone marrow (UBM) trans-
planted during the same period were selected as above and were
used as a control. Patients received Flu along with melphalan, bu-
sulfan, and total body irradiation in various combinations. Tacroli-
mus (Tac)+mycophenolate mofetil (n5 42) or Tac alone (n5 5)
were used for CB recipients and Tac+methotrexate was for all
UBM recipients as GVHD prophylaxis. 1 or 2-antigen mismatched
CB units were used at a median 2.56 (1.96-4.31) 107/kg of TNC
and 0.87 (0.4-6.32) 105/kg of CD34+ cells. 45 out of 47 CB recip-
ients achieved neutrophil recovery $500/ml at a median of 22 (13-
43) days, whereas all UBM recipients did at a median of 20 (16-41)
days (P5 0.17). In CB recipients, 30 patients were assessed donor-
recipient chimeric status in 16 days post-transplant, and, remark-
ably, 28 (93%) achieved complete (.90%) donor-type, while in
UBM recipients, 7 were assessed and only 2 (29%) did
(P\.0001). LR was assessed by defining the first day of 3 consecu-
tive blood test showed lymphocyte (Ly) $100/ml as the date of LR.
44 (94%) CB recipients achieved LR at a median of 15 (10-37)
days, while all UBM recipients did at a median of 20 (13-29)
days (P5 0.17). The cumulative incidences of LR achievement
up to day 19 were 646 0.5 in CB and 386 1.2 in UBM recipients
(P5.016). Flow cytometric analysis of Ly at around day 14 (13-17)
post-CBT, assessed in 30 patients, showed CD8+ T cell pedomi-
nance (506 5% of Ly). In conclusion, the results indicate
extremely powerful proliferative potential of CB Ly after transplan-
tation which may surpass that of UBM Ly.321
PREMALIGNANT AND MALIGNANT ORAL CHANGES FOLLOWING ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Mawardi, H.1, Elad, S.2, Correa, M.3, Stevenson, K.4, Woo, S.-B.1,5,
Lerman, M.1,5, Antin, J.6, Soiffer, R.6, Treister, N.1,5 1Harvard Schoolof Dental Medicine, Boston, MA; 2Hebrew University–Hadassah School
of Dental Medicine, Jerusalem, Israel; 3University of Campinas, Sao
Paulo, Brazil; 4Dana-Farber Cancer Institute, Boston, MA; 5Brigham
and Women’s Hospital, Boston, MA; 6Dana-Farber Cancer Institute,
Boston, MA
a) Background: Allogeneic hematopoietic cell transplantation
(HSCT) is associated with a wide range of complications and late ef-
fects, including secondary solid tumors, of which oral carcinoma is
one of the most common. The purpose of this study was to describe
the clinical characteristics of a large series of patients treated with
HSCT that subsequently developed oral premalignant or malignant
lesions.
b) Methods: The records of patients who received HSCT and
developed oral pre/malignant lesions at 3 centers were reviewed. De-
scriptive statistics included HSCT course including chronic graft-
versus-host disease (cGVHD) and details of oral neoplasm including
presentation, diagnosis and management; survival calculations were
also performed.
c) Results: Twenty-four patients were identified that developed
premalignant (n5 8) or malignant (n5 16) oral mucosal disease
at a median time of 3 and 9 years, respectively. Of the 22 that
had developed cGVHD, 95% (21/22) presented with oral features.
Of those that developed carcinoma, 25% had multifocal involve-
ment. The tongue was the most common site (n5 7; 44%), fol-
lowed by lower lip and buccal mucosa (n5 2; 12% for both
sites). Dysplasia preceded diagnosis of carcinoma in 13% of cases.
Localized recurrence occurred in 29% of cases with 5-year freedom
from recurrence of 46% 6 16. Five-year overall survival was 75%
6 22 for patients with premalignant changes and 67% 6 16 for pa-
tients with carcinoma.
d) Conclusions: Patients undergoing HSCT are at risk of develop-
ing new solid cancers, specifically in the mouth. As the majority of
patients in this series were previously diagnosed with oral cGVHD,
and many cases were multifocal/recurrent, this supports the theory
of field cancerization and suggests that these cancers may be more
aggressive than in non-HSCT patients. In addition, this highlights
the importance of comprehensive oral examination and vigilant fol-
low-up. Further studies examining the biological and molecular
processes of tumor development in this high-risk population are
needed.322
GENOTYPING OF HUMAN CYTOMEGALOVIRUS (HCMV) IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Dieamant, D.C.1, Bonon, S.H.A.1, Murakami, M.M.1, Costa, S.C.B.1,
Vigorito, A.C.2 1State University of Campinas-UNICAMP, Campinas,
Sa˜o Paulo, Brazil; 2State University of Campinas-UNICAMP, Campi-
nas, Sa˜o Paulo, Brazil
Based on sequence variation in theUL55 gene that encodes glyco-
protein B (gB), human cytomegalovirus (HCMV) can be classified
into four gB genotypes. Previous studies have suggested there could
be an association betweenCMVgB genotype and clinical outcome in
patients who underwent an allogeneic hematopoietic stem cell trans-
plant (HSCT).
Objectives: The goal of this study was to determine the distri-
bution of gB genotypes in allogeneic HSCT patients with CMV
infection and the effect of gB type on clinical outcome includ-
ing CMV disease. Study design: DNA was extracted directly
from the blood of 41 allogeneic HSCT recipients. Antigen
pp65-HCMV and HCMV-DNA was detected by AGM and
N-PCR, respectively. The gB genotype of CMV was determined
using the polymerase chain reaction to amplify a region of
UL55, followed by restriction analysis based on HinfI and
RsaI digestion.
Results:At a median time of 32 days after the transplant, 32/41
patients (78%) presented active HCMV infection detected by
AGM and/or N-PCR. So far, the distribution of HCMV gB ge-
notypes in 21/32 patients with HCMV active infection was as
follow: gB1, 9/21 (42,9%); gB2, 6/21 (28.6%); gB3, 2/21
(9,5%); gB4, 2/21 (9,5%) and two patients (9,5%) had mixed
